Amdocs (NASDAQ:DOX - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 6.859-7.116 for the period, compared to the consensus earnings per share estimate of 6.970. The company issued revenue guidance of $4.4 billion-$4.6 billion, compared to the consensus revenue estimate of $4.5 billion. Amdocs also updated its Q2 2025 guidance to 1.670-1.730 EPS.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the stock. StockNews.com raised shares of Amdocs from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Barclays decreased their target price on shares of Amdocs from $113.00 to $111.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Finally, Oppenheimer raised their target price on shares of Amdocs from $98.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $101.20.
Read Our Latest Research Report on DOX
Amdocs Trading Up 0.0 %
Shares of NASDAQ DOX traded up $0.01 during midday trading on Friday, reaching $85.97. 671,265 shares of the stock were exchanged, compared to its average volume of 632,452. The company has a 50 day simple moving average of $85.94 and a 200 day simple moving average of $86.43. The stock has a market capitalization of $9.71 billion, a P/E ratio of 19.95, a PEG ratio of 1.41 and a beta of 0.71. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.20 and a current ratio of 1.16. Amdocs has a twelve month low of $74.41 and a twelve month high of $94.04.
Amdocs (NASDAQ:DOX - Get Free Report) last posted its earnings results on Tuesday, February 4th. The technology company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.19). Amdocs had a net margin of 10.19% and a return on equity of 18.89%. As a group, equities analysts expect that Amdocs will post 6.21 earnings per share for the current year.
Amdocs Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Sunday, April 20th. Shareholders of record on Monday, March 31st will be given a $0.527 dividend. This represents a $2.11 annualized dividend and a yield of 2.45%. The ex-dividend date is Monday, March 31st. This is a boost from Amdocs's previous quarterly dividend of $0.48. Amdocs's dividend payout ratio (DPR) is currently 44.55%.
About Amdocs
(
Get Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Further Reading

Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.